trial
as of 2026-07-01MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)
NCTId NCT00482430
at a glance
Phase 2 · Completed
Enrollment 50 (actual)
Sponsored by Merck Sharp & Dohme LLC
Primary completion 2008-10
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Completed
Enrollment
50 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2007-09
Primary completion
2008-10
Eligibility
ALL · 21 Years · 55 Years
Interventions & indications
Sponsors
Merck Sharp & Dohme LLCLead Sponsor
Sites
0 total
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
50
Phase
PHASE2
Primary Completion Date
2008-10
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication